Results 31 to 40 of about 22,958 (212)
SAGE Open Medical Case Reports, 2021 Essential thrombocythemia is one of the famous diseases under the category of myeloproliferative disorder. It is an end result of a genetic mutation of one or more of the most frequent oncogenes such as Janos kinase 2 (JAK2), MPL proto-oncogene ...
Rehab Y AL-Ansari +3 more
doaj +1 more source
Emerging treatments for essential thrombocythemia
, 2011 Steven Okoli, Claire HarrisonDepartment of Haematology, Guy's and St Thomas' NHS Foundation Trust, Great Maze Pond, London, UKAbstract: In 1934, Epstein and Goedel used the term hemorrhagic thrombocythemia to describe a disorder ...
Okoli S +3 more
core +1 more source
Essential thrombocythemia, hemolytic anemia and hepatic cirrhosis: Could there be an association?
Hematology Reports, 2018 Vascular events are the most common clinical complication of essential thrombocythemia, leading to sign and symptoms of this disease. There are various sign and symptoms of essential thrombocythemia, such as thrombosis in artery or vein, and enlarged ...
Nata Pratama Hardjo Lugito +4 more
doaj +1 more source
Haematologica, 2019 Distinguishing essential thrombocythemia JAK2V617F from polycythemia vera is difficult because of shared mutation and phenotypic characteristics. The World Health Organization suggested hemoglobin and hematocrit values to diagnose polycythemia vera (PV),
Richard T. Silver, Spencer Krichevsky
doaj +1 more source
Dynamics of mutations in patients with essential thrombocythemia treated with imetelstat. [PDF]
, 2020 In a phase-2 study, the telomerase inhibitor imetelstat induced rapid hematologic responses in all patients with essential thrombocythemia who were refractory or intolerant to prior therapies.
Snyder, David S. +22 more
core +2 more sources
Essential thrombocythemia (ET) [PDF]
Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2011 The disease is a chronic myeloproliferative disorder originating from a mutated pluripotent stem cell capable of producing red blood cells, granulocytes and megakaryocytes. In some cases, B-lymphocyte involvement by the clonal proliferation was documented.
CUNEO, Antonio, CAVAZZINI, Francesco
openaire +2 more sources
The human myeloproliferative disorders: molecular pathogenesis and clonal heterogeneity [PDF]
, 2010 The classical myeloproliferative disorders (MPD), comprising essential thrombocythaemia (ET), polycythaemia vera (PV) and idiopathic myelofibrosis (IMF), are clonal premalignant haematopoietic neoplasms associated with activating mutations in signalling ...
core +2 more sources
iMeta, EarlyView.The Human Biomarker Navigator integrates the disease continuum, biomarker dynamics, cross‐organ biomarker networks, biomarker classification, and technology‐driven paradigms. It maps how biomarkers link multi‐system physiology and pathology across the nervous, respiratory, endocrine, circulatory, immune, digestive, urinary, reproductive, and ...
Meng‐Yao Li +29 more
wiley +1 more source
Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia. [PDF]
, 2015 BACKGROUND Imetelstat, a 13-mer oligonucleotide that is covalently modified with lipid extensions, competitively inhibits telomerase enzymatic activity. It has been shown to inhibit megakaryocytic proliferation in vitro in cells obtained from patients
Snyder, David S. +13 more
core +2 more sources
Recurrent thrombosis of splanchnic and lower extremity arteries with essential thrombocythemia
SAGE Open Medical Case Reports, 2019 Essential thrombocythemia is a myeloproliferative neoplasm characterized by platelet aggregation and thrombosis. Clinically, essential thrombocythemia increases the risk of both thrombosis and bleeding. Essential thrombocythemia is more involved in micro-
Sung Min Jung, Heungman Jun
doaj +1 more source